Therefore, the simultaneous targeting of the pre-proliferative protein RNR and the antiapoptotic protein BCL-2 may rationally enhance therapeutic efficacy in the clinical treatment of patients with AML. Here, BCL2 is linked to acute myeloid leukemia.